Yasushi Kisanuki, MD
Neurology · Gahanna, OHNPI 1518182419
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. Every reported general payment came from a single manufacturer, Mirum Pharmaceuticals, Inc..
Across 25 payments — averaging $2206.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirum Pharmaceuticals, Inc.$55K
Across 14 payments — averaging $11,072 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$123K
- Novartis$33K
What the payments were for
- Consulting fees$28,42052%
- Travel & lodging$24,25044%
- Food & beverage$1,1492%
- Education$1,3412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | 25 | $55,160 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CTEXLI$47,676
- (820) Cholbam$46,589
- Livmarli$6,558
How this compares
$55,160 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 25 | $807,059 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $19,168 |
| Dalfampridine ErDalfampridine | 30 | $9,264 |
| Baclofen | 371 | $8,985 |
| Gabapentin | 144 | $4,031 |
| Leucovorin Calcium | 13 | $2,414 |
| Propranolol Hcl ErPropranolol Hcl | 58 | $2,403 |
| Levocarnitine | 11 | $2,299 |
| Levetiracetam | 39 | $1,171 |
| Pregabalin | 80 | $1,062 |
| Dantrolene Sodium | 11 | $883 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $836 |
| Duloxetine Hcl | 25 | $676 |
| Lamotrigine | 23 | $540 |
| Primidone | 31 | $530 |
Paid to pharmacies, not to this prescriber.
Other neurology in Gahanna
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.